Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2000 Aug;2(3):116-23.
doi: 10.1016/S1525-1578(10)60625-3.

The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine

I A Sokolova  1 , K C Halling, R B Jenkins, H M Burkhardt, R G Meyer, S A Seelig, W King
Affiliations
Clinical Trial

The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine

I A Sokolova et al. J Mol Diagn. 2000 Aug.

Abstract

The purpose of this study was to develop a multitarget, multicolor fluorescence in situ hybridization (FISH) assay for the detection of urothelial carcinoma (UC) in urine specimens. Urinary cells obtained from voided urine specimens of 21 patients with UC and 9 normal donors were analyzed with nine different centromere enumeration probes and a single locus-specific indicator probe to determine an optimal set of FISH probes for UC detection. The four probes with the greatest sensitivity for UC detection were then labeled with a unique fluorophore and combined into a single probe set. The probes with the greatest combined sensitivity for UC detection were CEP3, CEP7, CEP17, and the 9p21 (P16) LSI. This probe set was used to evaluate urine specimens acquired from 179 patients for prospective testing (46 with biopsy-proven UC). FISH slides were evaluated by scanning the slide for cells with nuclear features suggestive of malignancy and assessing the FISH signal pattern of these cells for polysomy (ie, gains of two or more different chromosomes). A receiver operator characteristic curve revealed that a cutoff of 5 cells with polysomy as the positive criterion for cancer resulted in an overall sensitivity of 84.2% for patients with biopsy-proven UC and a specificity of 91.8% among patients with genitourinary disorders but no evidence of UC. This study demonstrates that a multitarget, multicolor FISH assay containing centromeric probes to chromosomes 3, 7, and 17 and a locus-specific probe to band 9p21 has high sensitivity and specificity for the detection of UC in voided urine specimens.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
A and B demonstrate that cells with FISH abnormalities frequently exhibit nuclear abnormalities and that these nuclear abnormalities can be used to facilitate scanning for FISH abnormal cells. Arrows in A point to abnormal nuclei as seen with DAPI stain only. Arrows in B point to the same abnormal nuclei and reveal that these cells have multiple copies of chromosomes 3 (red signals) and 7 (green signals).
Figure 2.
Figure 2.
Examples of FISH normal and abnormal cases with optimized probe set. A shows an example of a FISH normal cell from a normal urine donor. B shows an example of a FISH abnormal cell with polysomy from a patient with biopsy-proven UC after FISH. CEP7 (green), CEP3 (red), CEP17 (aqua), and LSI 9p21 (yellow).
Figure 3.
Figure 3.
Receiver-operator characteristic curve showing the sensitivity and specificity of the FISH assay for UC detection based on the number of cells with polysomy. This curve was determined from 46 patients with biopsy-proven UC (sensitivity) and 63 patients without evidence of bladder cancer (specificity). A cutoff of five or more cells with polysomy provided a sensitivity of 84.2% and specificity of 91.8%.
See this image and copyright information in PMC

References

    1. Messing EM, Catalona W: Urothelial tumors of the urinary tract. Walsh PC Retik AB Darracott Vaughan E Wein AJ eds. Campbell’s Urology 7th ed. 1998:2327-2410 W.B. Saunders Company Philadelphia
    1. Fitzgerald JM, Ramchurren N, Rieger K, Levesque P, Silverman M, Libertino JA, Summerhayes IC: Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. J Natl Cancer Inst 1995, 87:129-133 - PubMed
    1. Schmetter BS, Habicht KK, Lamm DL, Morales A, Bander NH, Grossman HB, Hanna MGJ, Silberman SR, Butman BT: A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J Urol 1997, 158:801-805 - PubMed
    1. Thomas L, Leyh H, Marberger M, Bombardieri E, Bassi P, Pagano F, Pansadoro V, Sternberg CN, Boccon-Gibod L, Ravery V, Le Guludec D, Meulemans A, Conort P, Ishak L: Multicenter trial of the quantitative BTA-TRAK assay in the detectin of bladder cancer. Clin Chem 1999, 45:472-477 - PubMed
    1. Maier U, Simak R, Neuhold N: The clinical value of urinary cytology: 12 years of experience with 615 patients. J Clin Pathol 1995, 48:314-317 - PMC - PubMed

Publication types

MeSH terms